BigHat Biosciences, a biotechnology company based in San Mateo, California, has successfully raised $75 million in a Series C financing round co-led by DFJ Growth and Premji Invest. This funding milestone, announced on October 2023, brings BigHat’s total funding to $223 million and is set to accelerate the development of its AI-driven protein therapeutics platform.
What Happened
BigHat Biosciences specializes in the development of protein-based medicines using an innovative AI platform that integrates molecular design with experimental validation. The company’s approach is unique in that it generates proprietary biological data specifically tailored to address particular drug discovery challenges, rather than relying solely on existing datasets. This process allows BigHat to continuously refine its AI models and improve the design of therapeutic candidates.
The newly secured funding will propel the clinical development of BigHat’s drug pipeline, including BHB810, its first AI-designed therapeutic currently in Phase 1 clinical trials. BHB810 is a novel CDH17-directed antibody-drug conjugate aimed at treating gastric cancer and other advanced gastrointestinal tumors. Additionally, BigHat is advancing BHB299, a T-cell engager targeting solid tumors expressing CEACAM6, with plans to begin human clinical trials by 2027.
BigHat’s Series C round saw participation from a consortium of investors, including Catalio Capital Management, LG Technology Ventures, and Sigmas Group, alongside existing investors like 8VC, Alexandria Venture Investments, and Amgen Ventures. The company also maintains strategic collaborations with major pharmaceutical entities such as Amgen, Merck, Johnson & Johnson, AbbVie, and Eli Lilly.
What This Means for Your Business
For AECM professionals and government contractors, this development signifies the growing importance of AI and biotechnology collaborations. BigHat’s model of integrating AI with experimental processes highlights the potential for significant advancements in drug development, offering new opportunities for partnerships and investments in the biotech sector.
The implications for compliance and procurement are substantial, as companies engaged in biotechnology will need to align with evolving standards and regulations around AI and data usage. The involvement of major pharmaceutical companies underscores the competitive advantage such collaborations can provide, potentially leading to faster drug development cycles and improved ROI.
What US Operators Should Watch
Key dates for stakeholders include the anticipated completion of BHB299’s preclinical development and the initiation of human trials in 2027. The continued evolution of AI-driven drug development platforms like BigHat’s could influence federal funding opportunities and regulatory frameworks, particularly those concerning AI and data compliance.
Stakeholders should also monitor BigHat’s strategic partnerships and collaborations, as these could present new avenues for investment and technological integration. As AI continues to play a pivotal role in biotechnology, staying updated on technological advancements and regulatory changes will be crucial for maintaining a competitive edge.
Source: https://pulse2.com/bighat-biosciences-raises-75-million-series-c/
Is your firm ready for what’s next?
VisioneerIT helps AECM and government contractors modernize operations, achieve compliance, and implement AI.
Explore VisioneerIT Solutions →
